Le Lézard
Classified in: Health, Science and technology, Business
Subject: LIC

FibroGenesis Announces Manufacturing Agreement with iBiologics


HOUSTON, Sept. 28, 2020 /PRNewswire/ -- FibroGenesis, the leading developer of fibroblast based therapeutic solutions for unmet medical needs, is pleased to announce it has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast cells to support FibroGenesis's growing chronic disease platform and ongoing clinical trials.

"We are extremely pleased to partner with iBiologics to manufacture our breakthrough fibroblasts," said Pete O'Heeron, CEO of FibroGenesis. "Our collaboration with iBiologics has produced the highest quality fibroblasts available and their adherence to GMP processes assures us of a reliable source for this unique cell line which will ultimately help patients suffering from chronic diseases."

"FibroGenesis has a unique and impressive platform technology and is positioned to secure its place as a premier provider of cell-based therapeutics and we look forward to being part of this process," said Francisco Silva, CEO of iBiologics.

About iBiologics

iBiologics is a leading CDMO for the development and manufacturing of autologous and allogeneic cell and gene therapy products.  iBiologics provides a unique combination of custom services to companies across all points of translational and clinical development.

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company developing an innovative solution for chronic disease treatment using human dermal fibroblasts. Currently, FibroGenesis holds 240+ U.S. and international issued patents/patents pending across a variety of clinical pathways, including Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. Funded entirely by angel investors, FibroGenesis represents the next generation of medical advancement in cell therapy.

Visit www.Fibro-Genesis.com.

 

SOURCE FibroGenesis


These press releases may also interest you

at 19:53
The Greater Toronto Airports Authority ("GTAA") today reported its financial and operating results for 2023.  Passenger activity significantly increased by 9.2 million, or 25.8 per cent, from 35.6 million to 44.8 million in 2023, when compared to...

at 19:45
North Coast Brewing Company (NCBC) announces an exceptional new barrel-aged beer. Born from a special collaboration between North Coast Brewing Company and Westward Whiskey, this limited offering of Barrel Aged Old Rasputin has matured for over a...

at 19:30
Robex Resources Inc. ("Robex" or the "Company") announces today that its Board of Directors has approved the implementation of the consolidation of the issued and outstanding common shares of the Company approved by its shareholders on June 29,...

at 19:30
ApartmentLove Inc. ("ApartmentLove" or the "Company"), a leading provider of online home, apartment, and vacation rental marketing services to property managers, owners, renters, and vacationers from around the world today announces a non-brokered...

at 19:30
Willow Biosciences Inc. ("Willow" or the "Company") , a leading biotechnology...

at 19:15
Extra Space Storage Inc. (the "Company") announced today it will release financial results for the three months ended March 31, 2024 on Tuesday, April 30, 2024 after the market closes. The Company will host a conference call at 1:00 p.m. Eastern...



News published on and distributed by: